Elevance Health (ELV) EBITDA (2009 - 2026)

Elevance Health (ELV) has 18 years of EBITDA data on file, last reported at $765.0 million in Q1 2026.

• EBITDA for Q1 2026 came in at $765.0 million, up 29.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 8.87% YoY), and the FY2025 annual result was $2.2 billion, up 6.97% from the prior year.
• EBITDA improved to $765.0 million in Q1 2026 per ELV's latest filing, from $493.0 million in the prior quarter.
• Over five years, EBITDA peaked at $765.0 million in Q1 2026 and troughed at $360.0 million in Q1 2022.
• A 5-year average of $489.4 million and a median of $493.0 million in 2023 frame the typical range for EBITDA.
• The sharpest annual moves came in 2023 and 2025: EBITDA jumped 41.82% in 2023, then slipped 6.45% in 2025.
• A 5-year view of EBITDA shows it stood at $373.0 million in 2022, then jumped by 41.82% to $529.0 million in 2023, then declined by 0.38% to $527.0 million in 2024, then slipped by 6.45% to $493.0 million in 2025, then surged by 55.17% to $765.0 million in 2026.
• Business Quant data shows ELV's EBITDA at $765.0 million in Q1 2026, $493.0 million in Q4 2025, and $625.0 million in Q3 2025.